Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer Ahead of Planned BLA Filing

Candel Therapeutics Inc. (Nasdaq: CADL) has appointed oncology commercial executive Mark Sims as Chief Commercial Officer as the clinical-stage biotechnology... Read More

The post Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer Ahead of Planned BLA Filing appeared first on citybiz.